News & Events



Charles River Plans to Acquire WuXi AppTec for 1.6 B

Charles River announced its plans to acquire WuXi AppTec, creating a global CRO to offer fully integrated drug development services from molecule creation to first-in-human testing. The combined company, which will retain the name Charles River, will offer enhanced support for your research programs through our comprehensive portfolio of early-stage drug development services and expanded global presence.

WuXi AppTec is a leading drug research and development outsourcing company with significant expertise in discovery chemistry. It was established in 2000 and has steadily grown to more than 4,000 employees with operations in China and the United States. Together with Charles River, a leading global provider of both research models and associated services as well as preclinical drug development services, the combined company will have 12,000 employees, providing unparalleled support for your early-stage drug development needs.

中国《生物医药‘十二五’发展规划》即将出炉

肝癌致癌基因取得重大发现

南通大学举行《北美华人生物医药协会归国代表团演讲会》

BIO Welcomes Zhangjiang Hi-Tech Park and China Medical City

US-China Collaboration to battle the oil spill

Smart underpants become personal monitor

中国公布《国家中长期人才发展规划纲要》

中国重新强调科技创新“举国体制”

Pain, Adenosine and Acupuncture

苏州工业园区第三批生物医药领军人物

New tooth growing from stem cell

Charles River Plans to Acquire WuXi AppTec for 1.6 B

Page: 1 | 2 | 3 | 4 | 5 |